CMPI's Business Model
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.checkmatepharma.com |
| CEO (Chief Executive Officer) | Barry A. Labinger |
| Number of Employees | |
| IPO date | August 7, 2020 |
CMPI Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 245 Main Street |
| City | Cambridge |
| State | MA |
| Phone | 617 682 3625 |
| Zip Code | 02142 |
| Other Identifiers | |
| CIK | 0001651431 |
| ISIN | US1628181083 |
| CUSIP | 162818108 |
| Open | 10.49 |
| Previous Close | 10.5 |
| Volume | 63.65 Thou. |
| Average Volume | 233 Thou. |
| Day’s Range | 10.49 – 10.5 |
| 52 Week Range | 10.49-10.5 |
| MA (50) | 8.6026 |
| MA (200) | 4.7758756 |
| Market Cap | 0 |
| Shares Out. | 0 |
| Earnings Date | May 12, 2022 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
